Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ZIDOVUDINE PLUS INTERFERON-ALPHA VERSUS ZIDOVUDINE ALONE IN HIV-INFECTED SYMPTOMATIC OR ASYMPTOMATIC PERSONS WITH CD4-THAN-150X10(6)( CELL COUNTS GREATER)I - RESULTS OF THE ZIDON TRIAL/
Autore:
FERNANDEZCRUZ E; LANG JM; FRISSEN J; FURNER V; CHATEAUVERT M; BOUCHER CAB; DOWD P; STEVENS J; GOLD J; MICHELMORE H; BENSON E; SPELMAN E; HOY J; WRIGHT E; FRENCH M; HUDSON J; MALLAL S; BODSWORTH N; STINGL G; MAYERHOFER S; KRONAWETTER M; TSOUKAS C; SZABO T; KATLAMA C; GUERMONPREZ G; RAFFI F; BILLAUD E; MILPIED B; BOURGEOT V; FLEISHMANN M; BARRIER JH; DELZANT G; WINTER C; MEHARZI J; TREPO C; COTTE L; ROUGIER P; HASSAIRI N; CHOUTET P; BESNIER JM; LAFEUILLADE A; RASOKAT H; GROSS G; MAUSCH HE; STRATIGOS J; POLYDOROV D; STAVRIANEAS N; KIOSSES V; MANDALAKI T; KARAFOULIDOU A; KARABINIS A; STERGIOU G; PLOUMIDES G; PITSAS A; TASSOPOULOS N; KOUTSOUNOPOULOS G; HATZAKIS A; MORONI M; DARMINIO A; BINI T; CHIODO F; COLANGELI V; RICCHI E; AIUTI F; FERRARA R; MEZZAROMA I; LANGE JMA; FRISSEN PHJ; SPRENGER HG; KROON FP; VANDERENDE ME; DEMARIE S; KOOPMANS PP; DOLMANS WMV; SCHREIJ GS; WEIGEL HM; TENNAPEL CHH; TENKATE RW; MARANON G; ZABAY JM; COSIN J; PENA JM; RUBIO R; RIBERA E; VAZQUEZ JMM; LEAL M; ANDREU J; CARTON JA; ASENSI V; GOMEZTRUJILLO F; ORIHUELA F; SERRANO C; FERRER E; MANDAL BK; JOHNSON M; MCKARTHY K; FARMER D; TANG A; MITCHELL SA; BROWN J; TOORAWA R; YEO J;
Indirizzi:
HOSP GEN GREGORIO MARANON,DEPT IMMUNOL,DOCTOR ESQUERDO 46 E-28007 MADRID SPAIN CHU STRASBOURG F-67000 STRASBOURG FRANCE ONZE LIEVE VROUW HOSP,DEPT INTERNAL MED AMSTERDAM NETHERLANDS ALBION ST CTR SYDNEY NSW AUSTRALIA ROYAL VICTORIA HOSP,MONTREAL CHEST HOSP CTR MONTREAL PQ H3A 1A1 CANADA UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,ANTIVIRAL THERAPY LAB 1105 AZ AMSTERDAM NETHERLANDS WELLCOME RES LABS,DEPT INFECT DIS BECKENHAM BR3 3BS KENT ENGLAND WELLCOME RES LABS,DEPT CLIN STAT & DATA HANDLING BECKENHAM BR3 3BS KENT ENGLAND
Titolo Testata:
AIDS
fascicolo: 9, volume: 9, anno: 1995,
pagine: 1025 - 1035
SICI:
0269-9370(1995)9:9<1025:ZPIVZA>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; REPLICATION INVITRO; KAPOSIS-SARCOMA; DOUBLE-BLIND; HTLV-III; THERAPY; AZT; RESISTANCE; AZIDOTHYMIDINE;
Keywords:
ZIDOVUDINE; INTERFERON-ALPHA; LYMPHOBLASTOID INTERFERON; HIV DISEASE; HIV CLINICAL TRIALS; ANTIVIRAL AGENTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
E. Fernandezcruz et al., "ZIDOVUDINE PLUS INTERFERON-ALPHA VERSUS ZIDOVUDINE ALONE IN HIV-INFECTED SYMPTOMATIC OR ASYMPTOMATIC PERSONS WITH CD4-THAN-150X10(6)( CELL COUNTS GREATER)I - RESULTS OF THE ZIDON TRIAL/", AIDS, 9(9), 1995, pp. 1025-1035

Abstract

Objective: To evaluate the efficacy and safety of zidovudine (ZDV) and lymphoblastoid interferon (IFN)-alpha combination therapy compared with ZDV monotherapy in HIV-infected subjects with CD4+ cell counts between 150 and 500 x 10(6)/l. Design: Open, randomized controlled trial with subjects stratified by the Centers for Disease Control and Prevention (CDC) 1986 classification of HIV disease (group II/III or IV). The study was amended to a sequential design in February 1992 to allow interim analyses to be conducted. Setting: Outpatient clinics in 45 hospitals in Europe, Australia and Canada. Participants: A total of 402 previously untreated subjects with symptomatic HIV infection (CDC groupIV) and CD4+ count 150-500x10(6)/l or asymptomatic HIV infection (CDCgroup II/III) with CD4+ count 150-350 x 10(6)/l. Interventions: ZDV 250 mg twice daily with or without 3 MU subcutaneous injections of lymphoblastoid IFN-alpha three times per week. Main outcome measures: Timeto development of a study endpoint defined as: progression from CDC group II/III to group IV, group IV non-AIDS to AIDS, or group IV AIDS to a second AIDS-defining condition; also CD4+ count to <50 x 10(6)/l on two occasions at least 1 month apart or HIV-related death irrespective of CDC group on entry. Results: There was no reduction in the rate of disease progression for patients receiving ZDV plus IFN-alpha compared with patients receiving ZDV alone. No major differences between the groups were seen for CD4+ counts or percentages, or p24 antigenaemia. In a subset of 70 patients, a similar proportion from both dose groups showed evidence of ZDV resistance after 48 weeks of treatment. Moreadverse experiences were seen in the ZDV/IFN-alpha group. Conclusions: Combination therapy with low dose lymphoblastoid IFN-alpha and ZDV revealed no clinical benefit compared with ZDV monotherapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 14:27:13